CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.


Begin main content


Last Updated: April 15, 2008
Result type: Reports
Project Number: SR0130-000
Product Line: Reimbursement Review

Generic Name: Adalimumab

Brand Name: Humira

Manufacturer: Abbott Laboratories, Limited

Therapeutic Area: Psoriasis

Indications: Psoriasis

Submission Type: Initial

Project Status: Complete

Date Recommendation Issued: October 16, 2008

Recommendation Type: List with clinical criteria and/or conditions